Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The New England Journal of Medicine

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

Biogen Idec launches online multiple sclerosis programme

MS Blueprint aims to help people with MS develop a personalised support plan

- PMLiVE

Pharma takes the ALS Ice Bucket Challenge

GSK, Evotec and Biogen Idec participate in the social media sensation

- PMLiVE

Biogen submits haemophilia drug for US approval

Step forward for its partnership with Swedish Orphan Biovitrum

- PMLiVE

Biogen Idec drops ALS drug dexpramipexole

Fails to achieve efficacy in phase III trial

- PMLiVE

Upcoming treatments for amyotrophic lateral sclerosis

While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed

- PMLiVE

Publicis Amsterdam wins Effie Award Silver for Dutch ALS Foundation

Hard-hitting campaign for amyotrophic lateral sclerosis (ALS) puts up sterling fight for sufferers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links